The National Health and Medical Research Council’s (NHMRC) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Guideline Development Committee (ME/CFS GDC) held its third meeting on Tuesday 9 December 2025. The committee discussed topics to be considered as part of the evidence review for the clinical practice guidelines for ME/CFS and related conditions, including Long COVID, postural orthostatic tachycardia syndrome (POTS) and fibromyalgia.

Date: Tuesday 9 December 2025
Time: 12:30 pm – 2:30 pm AEDT
Location: Virtual meeting

Key highlights

  • Members reviewed new declarations of interests and determined that all were low risk and that none required management strategies.
  • Members discussed the initial priority areas to be considered as part of the evidence evaluation, including:  
    • target populations
    • signs, symptoms and diagnosis of ME/CFS  
    • pharmacological interventions
    • non-pharmacological interventions
    • clinical care pathways.
  • Members agreed to finalise the topics to be included in the evidence review out of session.
  • Members agreed that working groups should be established so that in-depth work on the guidelines can be done in a timely manner. Members noted, however, that all decisions would be made by the committee as a whole.

Next steps

  • The next meeting of the ME/CFS GDC is planned for early 2026 and will focus on finalising topic prioritisation.